Q32 Bio logo

Q32 BioNASDAQ: QTTB

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

28 March 2018

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$401.35 M
-34%vs. 3y high
62%vs. sector
-vs. 3y high
-vs. sector
0%vs. 3y high
98%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 15 Nov 2024 21:20:00 GMT
$32.95-$2.68(-7.52%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

QTTB Latest News

Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 91.69%: Read This Before Placing a Bet
zacks.com12 August 2024 Sentiment: POSITIVE

The consensus price target hints at a 91.7% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Q32 Bio Joins Russell 3000® Index
prnewswire.com01 July 2024 Sentiment: POSITIVE

WALTHAM, Mass. , July 1, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that the company is joining the broad-market Russell 3000® Index at the conclusion of the 2024 Russell Indexes annual reconstitution, effective upon the U.S. market opening today, July 1, 2024.

What type of business is Q32 Bio?

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

What sector is Q32 Bio in?

Q32 Bio is in the Healthcare sector

What industry is Q32 Bio in?

Q32 Bio is in the Biotechnology industry

What country is Q32 Bio from?

Q32 Bio is headquartered in United States

When did Q32 Bio go public?

Q32 Bio initial public offering (IPO) was on 28 March 2018

What is Q32 Bio website?

https://www.q32bio.com

Is Q32 Bio in the S&P 500?

No, Q32 Bio is not included in the S&P 500 index

Is Q32 Bio in the NASDAQ 100?

No, Q32 Bio is not included in the NASDAQ 100 index

Is Q32 Bio in the Dow Jones?

No, Q32 Bio is not included in the Dow Jones index

When was Q32 Bio the previous earnings report?

No data

When does Q32 Bio earnings report?

The next expected earnings date for Q32 Bio is 28 February 2025